Cargando…

Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)

Although partial thickness burns are the most frequently reported burn injuries, there is no consensus on the optimal treatment. The objective of this study was to compare the clinical effectiveness and scar quality of Flaminal® Forte to silver sulfadiazine (Flamazine®) in the treatment of partial t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashaan, Zjir M., Krijnen, Pieta, Kwa, Kelly A.A., van der Vlies, Cornelis H., Schipper, Inger B., Breederveld, Roelf S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850327/
https://www.ncbi.nlm.nih.gov/pubmed/30675745
http://dx.doi.org/10.1111/wrr.12699
_version_ 1783469400753438720
author Rashaan, Zjir M.
Krijnen, Pieta
Kwa, Kelly A.A.
van der Vlies, Cornelis H.
Schipper, Inger B.
Breederveld, Roelf S.
author_facet Rashaan, Zjir M.
Krijnen, Pieta
Kwa, Kelly A.A.
van der Vlies, Cornelis H.
Schipper, Inger B.
Breederveld, Roelf S.
author_sort Rashaan, Zjir M.
collection PubMed
description Although partial thickness burns are the most frequently reported burn injuries, there is no consensus on the optimal treatment. The objective of this study was to compare the clinical effectiveness and scar quality of Flaminal® Forte to silver sulfadiazine (Flamazine®) in the treatment of partial thickness burns. In this two‐arm open label multicenter randomized controlled trial, adult patients with acute partial thickness burns and an affected total body surface area of less than 30% were randomized between Flaminal® Forte and Flamazine® and followed for 12 months. Dressing changes in the Flamazine® group were performed daily, and in the Flaminal® group during the first 3 days post burn and thereafter every other day until complete wound healing or surgery. Forty‐one patients were randomly allocated to Flaminal® Forte and 48 patients to Flamazine®. The primary outcome was time to wound healing, which did not differ between the groups: median 18 days with Flaminal® Forte (range 8–49 days) versus 16 days with Flamazine® (range 7–48 days; p = 0.24). Regarding the secondary outcomes during hospital admission, there were no statistically significant differences between the groups concerning need for surgery, pain scores, pruritus, or pain‐related and anticipatory anxiety. More patients in the Flaminal® group developed wound colonization (78% versus 32%, p < 0.001), but the treatment groups did not differ regarding the incidence of local infections and use of systemic antibiotics. In terms of scar quality, no statistically significant differences between both treatment groups were found regarding subjective scar assessment (Patient and Observer Scar Assessment Scale (POSAS)), scar melanin and pigmentation (DermaSpectrometer®), and scar elasticity and maximal extension (Cutometer®) during 12 month postburn. In conclusion, time to wound healing did not differ, but the use of Flaminal® Forte seemed favorable because less dressing changes are needed which lowers the burden of wound care.
format Online
Article
Text
id pubmed-6850327
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-68503272019-11-18 Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study) Rashaan, Zjir M. Krijnen, Pieta Kwa, Kelly A.A. van der Vlies, Cornelis H. Schipper, Inger B. Breederveld, Roelf S. Wound Repair Regen Original Research‐Clinical Science Although partial thickness burns are the most frequently reported burn injuries, there is no consensus on the optimal treatment. The objective of this study was to compare the clinical effectiveness and scar quality of Flaminal® Forte to silver sulfadiazine (Flamazine®) in the treatment of partial thickness burns. In this two‐arm open label multicenter randomized controlled trial, adult patients with acute partial thickness burns and an affected total body surface area of less than 30% were randomized between Flaminal® Forte and Flamazine® and followed for 12 months. Dressing changes in the Flamazine® group were performed daily, and in the Flaminal® group during the first 3 days post burn and thereafter every other day until complete wound healing or surgery. Forty‐one patients were randomly allocated to Flaminal® Forte and 48 patients to Flamazine®. The primary outcome was time to wound healing, which did not differ between the groups: median 18 days with Flaminal® Forte (range 8–49 days) versus 16 days with Flamazine® (range 7–48 days; p = 0.24). Regarding the secondary outcomes during hospital admission, there were no statistically significant differences between the groups concerning need for surgery, pain scores, pruritus, or pain‐related and anticipatory anxiety. More patients in the Flaminal® group developed wound colonization (78% versus 32%, p < 0.001), but the treatment groups did not differ regarding the incidence of local infections and use of systemic antibiotics. In terms of scar quality, no statistically significant differences between both treatment groups were found regarding subjective scar assessment (Patient and Observer Scar Assessment Scale (POSAS)), scar melanin and pigmentation (DermaSpectrometer®), and scar elasticity and maximal extension (Cutometer®) during 12 month postburn. In conclusion, time to wound healing did not differ, but the use of Flaminal® Forte seemed favorable because less dressing changes are needed which lowers the burden of wound care. John Wiley & Sons, Inc. 2019-02-11 2019 /pmc/articles/PMC6850327/ /pubmed/30675745 http://dx.doi.org/10.1111/wrr.12699 Text en © 2019 The Authors. Wound Repair and Regeneration published by Wiley Periodicals, Inc. on behalf of by the Wound Healing Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research‐Clinical Science
Rashaan, Zjir M.
Krijnen, Pieta
Kwa, Kelly A.A.
van der Vlies, Cornelis H.
Schipper, Inger B.
Breederveld, Roelf S.
Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
title Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
title_full Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
title_fullStr Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
title_full_unstemmed Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
title_short Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study)
title_sort flaminal® versus flamazine® in the treatment of partial thickness burns: a randomized controlled trial on clinical effectiveness and scar quality (flam study)
topic Original Research‐Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850327/
https://www.ncbi.nlm.nih.gov/pubmed/30675745
http://dx.doi.org/10.1111/wrr.12699
work_keys_str_mv AT rashaanzjirm flaminalversusflamazineinthetreatmentofpartialthicknessburnsarandomizedcontrolledtrialonclinicaleffectivenessandscarqualityflamstudy
AT krijnenpieta flaminalversusflamazineinthetreatmentofpartialthicknessburnsarandomizedcontrolledtrialonclinicaleffectivenessandscarqualityflamstudy
AT kwakellyaa flaminalversusflamazineinthetreatmentofpartialthicknessburnsarandomizedcontrolledtrialonclinicaleffectivenessandscarqualityflamstudy
AT vandervliescornelish flaminalversusflamazineinthetreatmentofpartialthicknessburnsarandomizedcontrolledtrialonclinicaleffectivenessandscarqualityflamstudy
AT schipperingerb flaminalversusflamazineinthetreatmentofpartialthicknessburnsarandomizedcontrolledtrialonclinicaleffectivenessandscarqualityflamstudy
AT breederveldroelfs flaminalversusflamazineinthetreatmentofpartialthicknessburnsarandomizedcontrolledtrialonclinicaleffectivenessandscarqualityflamstudy